Literature DB >> 18077675

Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms.

Emmanuel Planel1, Yoshitaka Tatebayashi, Tomohiro Miyasaka, Li Liu, Lili Wang, Mathieu Herman, W Haung Yu, Jose A Luchsinger, Brian Wadzinski, Karen E Duff, Akihiko Takashima.   

Abstract

Hyperphosphorylated tau is the major component of paired helical filaments in neurofibrillary tangles found in Alzheimer's disease (AD) brains, and tau hyperphosphorylation is thought to be a critical event in the pathogenesis of the disease. The large majority of AD cases is late onset and sporadic in origin, with aging as the most important risk factor. Insulin resistance, impaired glucose tolerance, and diabetes mellitus (DM) are other common syndromes in the elderly also strongly age dependent, and there is evidence supporting a link between insulin dysfunction and AD. To investigate the possibility that insulin dysfunction might promote tau pathology, we induced insulin deficiency and caused DM in mice with streptozotocin (STZ). A mild hyperphosphorylation of tau could be detected 10, 20, and 30 d after STZ injection, and a massive hyperphosphorylation of tau was observed after 40 d. The robust hyperphosphorylation of tau was localized in the axons and neuropil, and prevented tau binding to microtubules. Neither mild nor massive tau phosphorylation induced tau aggregation. Body temperature of the STZ-treated mice did not differ from control animals during 30 d, but dropped significantly thereafter. No change in beta-amyloid (Abeta) precursor protein (APP), APP C-terminal fragments, or Abeta levels were observed in STZ-treated mice; however, cellular protein phosphatase 2A activity was significantly decreased. Together, these data indicate that insulin dysfunction induced abnormal tau hyperphosphorylation through two distinct mechanisms: one was consequent to hypothermia; the other was temperature-independent, inherent to insulin depletion, and probably caused by inhibition of phosphatase activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077675      PMCID: PMC6673606          DOI: 10.1523/JNEUROSCI.3949-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  93 in total

Review 1.  Role of insulin resistance in Alzheimer's disease.

Authors:  Zhiyou Cai; Ming Xiao; Liying Chang; Liang-Jun Yan
Journal:  Metab Brain Dis       Date:  2014-11-16       Impact factor: 3.584

2.  mTOR-mediated hyperphosphorylation of tau in the hippocampus is involved in cognitive deficits in streptozotocin-induced diabetic mice.

Authors:  Shan Wang; Shan-lei Zhou; Fang-yuan Min; Jin-ju Ma; Xia-jie Shi; Erika Bereczki; Jing Wu
Journal:  Metab Brain Dis       Date:  2014-03-30       Impact factor: 3.584

3.  Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice.

Authors:  Yanxing Chen; Zhihou Liang; Zhu Tian; Julie Blanchard; Chun-Ling Dai; Sonia Chalbot; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Mol Neurobiol       Date:  2013-08-31       Impact factor: 5.590

Review 4.  JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities.

Authors:  Sidharth Mehan; Harikesh Meena; Deepak Sharma; Rameshwar Sankhla
Journal:  J Mol Neurosci       Date:  2010-09-28       Impact factor: 3.444

5.  Experimental induction of type 2 diabetes in aging-accelerated mice triggered Alzheimer-like pathology and memory deficits.

Authors:  Jogender Mehla; Balwantsinh C Chauhan; Neelima B Chauhan
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells.

Authors:  Steven J Greco; Sraboni Sarkar; Jane M Johnston; Xiongwei Zhu; Bo Su; Gemma Casadesus; J Wesson Ashford; Mark A Smith; Nikolaos Tezapsidis
Journal:  Biochem Biophys Res Commun       Date:  2008-09-16       Impact factor: 3.575

Review 7.  Human cerebral neuropathology of Type 2 diabetes mellitus.

Authors:  Peter T Nelson; Charles D Smith; Erin A Abner; Frederick A Schmitt; Stephen W Scheff; Gregory J Davis; Jeffrey N Keller; Gregory A Jicha; Daron Davis; Wang Wang-Xia; Adria Hartman; Douglas G Katz; William R Markesbery
Journal:  Biochim Biophys Acta       Date:  2008-08-22

8.  Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.

Authors:  Suzanne Craft; Laura D Baker; Thomas J Montine; Satoshi Minoshima; G Stennis Watson; Amy Claxton; Matthew Arbuckle; Maureen Callaghan; Elaine Tsai; Stephen R Plymate; Pattie S Green; James Leverenz; Donna Cross; Brooke Gerton
Journal:  Arch Neurol       Date:  2011-09-12

Review 9.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

10.  Hyperglycemia-induced tau cleavage in vitro and in vivo: a possible link between diabetes and Alzheimer's disease.

Authors:  Bhumsoo Kim; Carey Backus; Sangsu Oh; Eva L Feldman
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.